Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial
Authors
Keywords
Chemokine, Micromilieu, PD-1 blockade, Mismatch repair proficient, Colorectal cancer
Journal
EUROPEAN JOURNAL OF CANCER
Volume 167, Issue -, Pages 112-122
Publisher
Elsevier BV
Online
2022-04-13
DOI
10.1016/j.ejca.2022.03.017
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC).
- (2022) Afsaneh Barzi et al. JOURNAL OF CLINICAL ONCOLOGY
- ARID1A mutation may define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer
- (2021) Amir Mehrvarz Sarshekeh et al. CLINICAL CANCER RESEARCH
- Macrophages are metabolically heterogeneous within the tumor microenvironment
- (2021) Xenia Geeraerts et al. Cell Reports
- Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects
- (2021) Meggy Suarez-Carmona et al. Journal for ImmunoTherapy of Cancer
- Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer
- (2021) Wei Yu et al. Journal of Oncology
- Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)
- (2020) Ryoji Kato et al. Journal for ImmunoTherapy of Cancer
- Global Burden of 5 Major Types Of Gastrointestinal Cancer
- (2020) Melina Arnold et al. GASTROENTEROLOGY
- Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
- (2020) Shota Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer
- (2020) Eric X. Chen et al. JAMA Oncology
- Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
- (2020) Albiruni RA Razak et al. Journal for ImmunoTherapy of Cancer
- Differential Analyses of Peripheral Blood Parameters in CCR5 Inhibition-treated Colorectal Cancer Patients Reveal Dynamic Changes Linked to Clinical Outcomes
- (2020) AZAZ AHMED et al. ANTICANCER RESEARCH
- Treatment sequencing in metastatic colorectal cancer
- (2019) D.P. Modest et al. EUROPEAN JOURNAL OF CANCER
- Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer
- (2019) Jakob Nikolas Kather et al. BRITISH JOURNAL OF CANCER
- Targeting Tumor-Associated Macrophages in Cancer
- (2019) Paulina Pathria et al. TRENDS IN IMMUNOLOGY
- Recent Advances targeting CCR5 for Cancer and its Role in Immuno-Oncology
- (2019) Xuanmao Jiao et al. CANCER RESEARCH
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- (2019) Cathy Eng et al. LANCET ONCOLOGY
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- (2019) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Topography of cancer-associated immune cells in human solid tumors
- (2018) Jakob Nikolas Kather et al. eLife
- The delicate balance of macrophages in colorectal cancer; their role in tumour development and therapeutic potential
- (2017) R. Braster et al. IMMUNOBIOLOGY
- Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival
- (2017) Anna Berthel et al. OncoImmunology
- Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients
- (2016) Niels Halama et al. CANCER CELL
- Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
- (2016) Bernhard Mlecnik et al. IMMUNITY
- Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancer-associated fibroblast accumulation
- (2016) Yamato Tanabe et al. Oncotarget
- CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells
- (2015) Asim Pervaiz et al. MEDICAL ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-10 enhances the phenotype of M2 macrophages induced by IL-4 and confers the ability to increase eosinophil migration
- (2014) Naoyuki Makita et al. INTERNATIONAL IMMUNOLOGY
- CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination
- (2014) Andrea Mencarelli et al. Translational Oncology
- Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration
- (2013) Niels Halama et al. OncoImmunology
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sequential metastases of colorectal cancer
- (2012) Sophia Keim et al. OncoImmunology
- Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy
- (2011) N. Halama et al. CANCER RESEARCH
- Natural Killer Cells are Scarce in Colorectal Carcinoma Tissue Despite High Levels of Chemokines and Cytokines
- (2011) N. Halama et al. CLINICAL CANCER RESEARCH
- In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction
- (2010) N. R. Blatner et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Survival after hepatic resection of colorectal cancer metastases
- (2009) Douglas J. Robertson et al. CANCER
- Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers
- (2008) Samantha Abel et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started